Excerpt from latest PR explaining use of funding:
"The funding will enable Growlife to make three important advancements in the organization. First, retire some of the diluting debt that is weighing down the balance sheet. With the improved terms, the company will allocate some of the funds towards paying off more expensive debt. Second is to expand the current base business which has proven rapid growth through the integration of EZ-CLONE and its high margin manufacturing business. This unit needs further investment into sales and marketing as it continues to capture market share. Finally, this funding will be used to execute on the market oppotunity of hemp cloning by enabling the company to introduce new high margin CBD-hemp clones to GrowLife's extensive network of plant cultivators across the nation."
This is print, not my opinion. This seems to directly contradict some of the conjecture floating around on this board. Again, this is publicly printed by the company and not my opinion.
News 
Market Data 
Discover 
